NEW YORK, March 5, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pfizer Inc. Analyst Notes
On March 3, 2014, Pfizer Inc.'s (Pfizer) stock decreased 0.40% to end the day at $31.98, compared to the previous day's closing price at $32.11. Pfizer's stock decreased 0.03% over the past three trading days, compared to the Dow Jones Industrial Average which went down 0.19% during the same trading period. The full analyst notes on Pfizer Inc. are available to download free of charge at:
Dendreon Corp. Analyst Notes
On March 3, 2014, Dendreon Corp. (Dendreon) reported its Q4 2013 and full-year 2013 financial results. For Q4 2013, net product revenues totaled $74.8 million compared to $85.5 million in Q4 2012. For full year 2013, net product revenue totaled $283.7 million, down 12.8% YoY. Full-year net loss was $296.8 million or $1.95 per diluted share, compared to $393.6 million or $2.65 per share in full year 2012. "During the fourth quarter, our results were driven by strong growth in our oncology accounts as well as improvements in urology and academic accounts," said John H. Johnson, Chairman, President and CEO of Dendreon. "We expect our first quarter 2014 revenues to be consistent with our first quarter 2013 results. We continue to be on track on our restructuring and cost reduction plan to accelerate the path to profitability. We are focused on becoming cash flow breakeven as soon as possible." The full analyst notes on Dendreon Corp. are available to download free of charge at:
DepoMed Inc. Analyst Notes
On February 25, 2014, DepoMed Inc. (Depomed) reported its preliminary, unaudited Q4 2013 financial results. The Company's preliminary information suggested that product sales are expected to be c. $18.8 million for Q4 2013 compared to $12.5 million in Q4 2012, and $58.3 million for full year 2013 compared to $27.5 million in 2012. According to the Company, for Q4 2013, license and other revenue is expected to be c. $3.3 million while royalty revenue is expected to be $0.4 million. Depomed anticipates Q4 2013 total operating expenses to be $31 million. "2013 was a transformational year for Depomed," noted Jim Schoeneck, President and CEO of Depomed. "We executed a series of transactions that cement our position as a leading specialty pharmaceutical company in pain and neurology. With $276 million in purchasing power pending final determination of our 2013 income taxes, we have the financial resources to continue to build our portfolio of high growth products in pain, neurology and adjacent areas." The full analyst notes on DepoMed Inc. are available to download free of charge at:
Globus Medical, Inc. Analyst Notes
On February 26, 2014, Globus Medical, Inc. (Globus) reported its Q4 2013 financial results. For the quarter, the Company registered worldwide sales of $115.2 million, up 14.6% YoY. Q4 2013 net income totaled $21.0 million or $0.22 per diluted share, compared to $20.8 million or $0.22 per diluted share in Q4 2012. For full year 2013, worldwide sales totaled $434.5 million, up 12.6% YoY. Full-year 2013 net income was $68.6 million or $0.73 per diluted share, compared to $73.8 million or $0.80 per diluted share in 2012. "2013 was an outstanding year for Globus Medical. Sales grew by 12.6%, reaching $434.5 million; our full year Adjusted EBITDA was 34.7% of sales; we launched 16 new products; and we completed the acquisition of Excelsius Surgical," commented David Paul, Chairman and CEO. "This performance was the result of consistent, sustained execution of our strategy of combining robust product innovation and continued sales force expansion with disciplined expense control. I am very proud of the performance of our team in 2013 and continue to be confident in our ability to produce industry leading growth and outstanding profitability." The full analyst notes on Globus Medical, Inc. are available to download free of charge at:
Array BioPharma, Inc. Analyst Notes
On March 3, 2014, Array BioPharma Inc. (Array) reported full results from a randomized Phase 2 trial of ARRY 502 in patients with mild to moderate Th2-Driven Asthma. The results presented at the 2014 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting suggested that ARRY-502 met the primary endpoint in the trial, showing improved pre-bronchodilator Forced Expiratory Volume in one second (FEV1), a measure of lung function, by 3.9% versus placebo, achieving statistical significance. According to the release, ARRY-502 was well tolerated, with fewer adverse events in the ARRY-502 group as compared to the placebo group, including fewer asthma exacerbations. Ron Squarer, CEO of Array, noted, "With many asthma patients poorly controlled on currently available therapies, especially among severe asthmatics, an oral drug targeting a novel anti-inflammatory mechanism may present an important new option for millions of patients. We are seeking an appropriate partner to develop ARRY-502 to its full potential." The full analyst notes on Array BioPharma, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review